Seloken ZOC Forðatafla 190 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

seloken zoc forðatafla 190 mg

recordati ireland limited* - metoprololum súkkínat - forðatafla - 190 mg

Veraloc Retard Forðatafla 200 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

veraloc retard forðatafla 200 mg

orion corporation - verapamilum hýdróklóríð - forðatafla - 200 mg

Attentin Tafla 10 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

attentin tafla 10 mg

medice arzneimittel pütter gmbh & co. kg* - dexamfetaminum súlfat - tafla - 10 mg

Attentin Tafla 20 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

attentin tafla 20 mg

medice arzneimittel pütter gmbh & co. kg* - dexamfetaminum súlfat - tafla - 20 mg

Attentin Tafla 5 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

attentin tafla 5 mg

medice arzneimittel pütter gmbh & co. kg* - dexamfetaminum súlfat - tafla - 5 mg

Isoptin retard Forðatafla 120 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

isoptin retard forðatafla 120 mg

viatris aps - verapamilum hýdróklóríð - forðatafla - 120 mg

Anafranil Húðuð tafla 25 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

anafranil húðuð tafla 25 mg

pharmaand gmbh - clomipraminum hýdróklóríð - húðuð tafla - 25 mg

Decortin H Tafla 5 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

decortin h tafla 5 mg

merck ab - prednisolonum inn - tafla - 5 mg

Kapruvia Evropska unija - islandščina - EMA (European Medicines Agency)

kapruvia

vifor fresenius medical care renal pharma france - difelikefalin - pruritus - Öll önnur lækningavörur - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.

Binocrit Evropska unija - islandščina - EMA (European Medicines Agency)

binocrit

sandoz gmbh - epóetín alfa - anemia; kidney failure, chronic - sýklalyf - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. hjarta stöðu, fyrirfram núverandi blóðleysi á að byrja í lyfjameðferð).